Skip to main content
Top
Published in: Thrombosis Journal 1/2016

Open Access 01-12-2016 | Original basic research

Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database

Authors: Stéphane Bouée, Corinne Emery, Adeline Samson, Julie Gourmelen, Cécile Bailly, François-Emery Cotté

Published in: Thrombosis Journal | Issue 1/2016

Login to get access

Abstract

Background

Data estimating the annual incidence of venous thromboembolism (VTE) in France, taking into account both hospital and community settings, are very lacking.
This study aimed to estimate the annual incidence of VTE (pulmonary embolism (PE) and deep vein thrombosis (DVT)) in France in 2011 in “real world” population.

Methods

This was a longitudinal insurance claims study of the incidence of VTE in France over 2 years (2010 and 2011). The data analysis was performed using the EGB (Echantillon Généraliste des Bénéficiaires) database, a randomly selected sample of the French national insurance database (CNAMTS) which covers 77 % of the population. All adult patients experiencing a VTE event during the study period were analysed. Recurrence rate of VTE and all-cause mortality rate were also estimated over a 12-month follow-up period.

Results

The estimated annual incidence of VTE in France was 184.0 per 100 000 subjects, corresponding to a total of 119 670 events countrywide. The estimated incidence of DVT and PE were respectively 119.8 and 64.2 per 100 000 subjects. Annual recurrence of VTE was reported in 5.5 % (n = 99) patients, with a significantly higher recurrence rate in patients with PE than those with DVT (p = 0.02). Overall, 6.2 % (n = 112) of patients had died over the 12-month follow-up (respectively 10.2 and 7.7 % of patients with DVT and PE).

Discussion

To our knowledge, this analysis is the first to estimate the annual incidence of VTE in France using exhaustive data from the EGB database. This has allowed the incidence of DVT in the community to be documented, which to date has not been characterised. Previous studies in France have been limited to the hospital setting and have yielded incidence rates comparable to ours.

Conclusions

This analysis is the first to estimate the annual incidence of VTE in France using exhaustive data from the EGB database. This study showed that the incidence and the burden of the disease remains elevated.
Literature
1.
go back to reference Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46.CrossRefPubMed Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46.CrossRefPubMed
2.
go back to reference Pendleton R, Wheeler M, Rodgers G. Venous thromboembolism prevention in the acutely III medical patient : A review of the literature and focus on special patient populations, vol. 79. New York, NY, ETATS-UNIS: Wiley-Liss; 2005. Pendleton R, Wheeler M, Rodgers G. Venous thromboembolism prevention in the acutely III medical patient : A review of the literature and focus on special patient populations, vol. 79. New York, NY, ETATS-UNIS: Wiley-Liss; 2005.
3.
go back to reference Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–8.CrossRefPubMed Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–8.CrossRefPubMed
4.
go back to reference Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.CrossRefPubMed Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.CrossRefPubMed
5.
go back to reference Nicolaides A, Breddin K, Carpentier P, Coccheri S, Conard J, De Stefano V, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25(2):101–61. Nicolaides A, Breddin K, Carpentier P, Coccheri S, Conard J, De Stefano V, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25(2):101–61.
6.
go back to reference Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657–60.PubMed Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657–60.PubMed
7.
go back to reference Olié V, Chin F, Lamarche-Vadel A, De Peretti C. La maladie veineuse thromboembolique : patients hospitalisés et mortalité en France en 2010. Bull Epidémiol Hebd. 2013;33–34:417–23. Olié V, Chin F, Lamarche-Vadel A, De Peretti C. La maladie veineuse thromboembolique : patients hospitalisés et mortalité en France en 2010. Bull Epidémiol Hebd. 2013;33–34:417–23.
8.
go back to reference Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;54(4):286–90.CrossRef Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;54(4):286–90.CrossRef
9.
go back to reference De Roquefeuil L, Studer A, Neumann A, Merlière Y. The Echantillon généraliste de bénéficiaires: representativeness, scope and limits. Pratiques et Organisation des Soins. 2009;40(3):213–23.CrossRef De Roquefeuil L, Studer A, Neumann A, Merlière Y. The Echantillon généraliste de bénéficiaires: representativeness, scope and limits. Pratiques et Organisation des Soins. 2009;40(3):213–23.CrossRef
10.
go back to reference Institut National de la Statistique et des Etudes Economiques. Population totale par sexe et âge au 1er janvier 2011, France. 2011. Institut National de la Statistique et des Etudes Economiques. Population totale par sexe et âge au 1er janvier 2011, France. 2011.
11.
go back to reference Benard E, Lafuma A, Ravaud P. Epidemiology of venous thromboembolic disease. Presse Med. 2005;34(6):415–9.CrossRefPubMed Benard E, Lafuma A, Ravaud P. Epidemiology of venous thromboembolic disease. Presse Med. 2005;34(6):415–9.CrossRefPubMed
12.
go back to reference Guijarro R, Montes J, Sanroman C, Monreal M. Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. Eur J Intern Med. 2008;19(6):443–6.CrossRefPubMed Guijarro R, Montes J, Sanroman C, Monreal M. Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. Eur J Intern Med. 2008;19(6):443–6.CrossRefPubMed
13.
go back to reference Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.CrossRefPubMed Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.CrossRefPubMed
14.
go back to reference Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.CrossRefPubMed Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.CrossRefPubMed
15.
go back to reference Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.CrossRefPubMed Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.CrossRefPubMed
16.
go back to reference Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.CrossRefPubMed Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.CrossRefPubMed
17.
go back to reference Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769–74.CrossRefPubMed Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769–74.CrossRefPubMed
18.
go back to reference Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton 3rd LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761–8.CrossRefPubMed Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton 3rd LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761–8.CrossRefPubMed
19.
go back to reference Olie V, Zhu T, Martinez I, Scarabin PY, Emmerich J. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res. 2012;130(1):16–20.CrossRefPubMed Olie V, Zhu T, Martinez I, Scarabin PY, Emmerich J. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res. 2012;130(1):16–20.CrossRefPubMed
20.
go back to reference Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.CrossRefPubMed Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.CrossRefPubMed
21.
go back to reference Nieto JA, De Tuesta AD, Marchena PJ, Tiberio G, Todoli JA, Samperiz AL, et al. Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE). J Thromb Haemost. 2005;3(4):703–9.CrossRefPubMed Nieto JA, De Tuesta AD, Marchena PJ, Tiberio G, Todoli JA, Samperiz AL, et al. Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE). J Thromb Haemost. 2005;3(4):703–9.CrossRefPubMed
22.
go back to reference Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev. 2010;24(4-5):171–8.CrossRefPubMed Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev. 2010;24(4-5):171–8.CrossRefPubMed
23.
go back to reference Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost. 2010;8(9):1933–42.CrossRefPubMed Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost. 2010;8(9):1933–42.CrossRefPubMed
24.
go back to reference Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167(9):935–43.CrossRefPubMed Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167(9):935–43.CrossRefPubMed
25.
go back to reference Sevestre MA, Quashie C, Genty C, Rolland C, Quere I, Bosson JL. Clinical presentation and mortality in pulmonary embolism: the Optimev study. J Mal Vasc. 2010;35(4):242–9.CrossRefPubMed Sevestre MA, Quashie C, Genty C, Rolland C, Quere I, Bosson JL. Clinical presentation and mortality in pulmonary embolism: the Optimev study. J Mal Vasc. 2010;35(4):242–9.CrossRefPubMed
26.
go back to reference Agence Nationale de Sécurité du Médicament et des produits de santé. Prévention et traitement de la maladie thromboembolique veineuse en médecine. 2009. Agence Nationale de Sécurité du Médicament et des produits de santé. Prévention et traitement de la maladie thromboembolique veineuse en médecine. 2009.
27.
go back to reference Nicolaides A, Fareed J, Kakkar A, Comerota AJ, Goldhaber SZ, Hull RD, et al. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Int Angiol. 2013;32(2):132–9. Nicolaides A, Fareed J, Kakkar A, Comerota AJ, Goldhaber SZ, Hull RD, et al. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Int Angiol. 2013;32(2):132–9.
28.
go back to reference Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–494S.PubMedCentralCrossRefPubMed Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–494S.PubMedCentralCrossRefPubMed
29.
go back to reference Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.CrossRefPubMed Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.CrossRefPubMed
30.
go back to reference Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011;9(7):841–4.CrossRefPubMed Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011;9(7):841–4.CrossRefPubMed
31.
go back to reference Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMed Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMed
32.
go back to reference Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.CrossRefPubMed Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.CrossRefPubMed
33.
go back to reference Santos-Gallego CG, Badimón L, Badimón JJ. Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur Heart J Suppl. 2014;16(Suppl A):A56–60.CrossRef Santos-Gallego CG, Badimón L, Badimón JJ. Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur Heart J Suppl. 2014;16(Suppl A):A56–60.CrossRef
Metadata
Title
Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database
Authors
Stéphane Bouée
Corinne Emery
Adeline Samson
Julie Gourmelen
Cécile Bailly
François-Emery Cotté
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2016
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-016-0078-0

Other articles of this Issue 1/2016

Thrombosis Journal 1/2016 Go to the issue